Personal investment isn’t a liability in biotech leadership, but rather, a competitive advantage, writes Lisa Ricciardi, CEO ...

GLP-1 therapies created a consumer-driven market for pharmaceuticals that pairs digital access, partnerships, and retention ...

FDA’s final SIUU guidance loosens some off-label communication rules, but drugmakers still face strict compliance demands to ...

For much of the past two decades, the geography of pharmaceutical innovation was relatively stable. Discovery and capital clustered in hubs such as Boston, San Diego, and Basel. Asia played an ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, ...

Life sciences startups have long felt the gravitational pull of Boston and San Francisco when looking to raise capital, expand, and recruit talent. These two coastal regions, with an established ...

For many families living with rare pediatric diseases, hope often arrives quietly — after years of uncertainty, missed diagnoses, and being told that treatment may never come in time. For Lindsey ...

Each January, the J.P. Morgan Healthcare Conference helps to set the biopharmaceutical industry agenda for the coming year, and more suits can be seen on the streets of San Francisco than during any ...

Life sciences organizations invest heavily in marketing visibility. Most maintain a website, actively use LinkedIn, and participate in industry events. These efforts signal credibility, momentum, and ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...

During a July episode of the Business of Biotech, Ebrahim Delpassand, M.D., founder, chairman, and CEO at RadioMedix, pointed out the importance of knowing, as a company, what you do best. It won’t be ...